Patent ID: 11866788
Assignee: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
Field: Biotechnology (Chemistry)
Classification: CPC C | IPC C

Claim 2:
3. A method of identifying whether a subject is at risk for having a MYC-driven cancer, the method comprising:
(a) obtaining a biological sample from the subject;
(b) preparing cDNA from mRNA in the biological sample using primers comprising a sequence complementary to a circPVT1_212 splice variant (SEQ ID NO: 1) but not to a wild type form of PVT1 to produce prepared cDNA;
(c) determining an expression level of the circPVT1_212 splice variant (SEQ ID NO: 1) in the biological sample; and
(d) identifying whether the subject is at risk for having the MYC-driven cancer based on the expression level of the circPVT1_212 splice variant (SEQ ID NO: 1), wherein the MYC-driven cancer comprises a MYC-driven 8q24 gain medulloblastoma, wherein the MYC-driven 8q24 gain medulloblastoma comprises a subgroup 3, subgroup 4, Wnt, or Shh type medulloblastoma, and wherein the subject is stratified as having a subgroup 4 type medulloblastoma if circPVT1_212 splice variant expression level is 2 to 15 fold elevated compared to a reference value, wherein the reference value is the expression level of circPVT1_212 splice variant in a non-tumor sample.